Clinical Trial Update: Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of GSK1572932A as adjuvant therapy in tumor-antigen-positive non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GSK1572932A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell | Phase 1 | Status: TERMINATED